Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Margetuximab-cmkb |
| Trade Name | Margenza |
| Synonyms | MGAH22|MGAH-22 |
| Drug Descriptions |
Margenza (margetuximab-cmkb) is a monoclonal antibody that binds ERBB2 (HER2) and induces antitumor response against ERBB2 (HER2)-expressing tumor cells (PMID: 22129105, PMID: 32653053). Margenza (margetuximab-cmkb) in combination with chemotherapy is FDA approved for use in patients with metastatic ERBB2 (HER2)-positive breast cancer who had received two or more prior anti-ERBB2 (HER2) therapies (FDA.gov). |
| DrugClasses | HER2 (ERBB2) Antibody 79 |
| CAS Registry Number | 1350624-75-7 |
| NCIT ID | C91733 |